Cyclopamine

For research use only. Not for use in humans.

目录号：S1146 别名： 11-deoxojervine 中文名称：环巴胺

CAS No. 4449-51-8

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

规格

价格

库存

购买数量

5mg	RMB 1227.56	现货
25mg	RMB 3037.37	现货
50mg	RMB 3833.48	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Cyclopamine发表文献110篇：

Nature, 2021, 10.1038/s41586-021-03703-z

PubMed: 34234347 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Cell Rep, 2022, 38(7):110379

PubMed: 35172130 ( click the link to review the publication )

Cell Death Dis, 2022, 13(2):136

PubMed: 35145058 ( click the link to review the publication )

Oxid Med Cell Longev, 2022, 2022:9955677

PubMed: 35265269 ( click the link to review the publication )

Pharmacol Res, 2022, 178:106139

PubMed: 35202822 ( click the link to review the publication )

J Mol Cell Biol, 2022, mjab082

PubMed: 35040952 ( click the link to review the publication )

Development, 2022, 149(1)dev200021

PubMed: 35020897 ( click the link to review the publication )

Sci Rep, 2022, 12(1):359

PubMed: 35013404 ( click the link to review the publication )

Adv Sci (Weinh), 2021, e2103360

PubMed: 34918496 ( click the link to review the publication )

Neuron, 2021, S0896-6273(21)00506-7

PubMed: 34407390 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(29)e2101783118

PubMed: 34230098 ( click the link to review the publication )

Cancer Res, 2021, canres.0198.2021

PubMed: 34167949 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)418

PubMed: 33499351 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):459

PubMed: 33966040 ( click the link to review the publication )

Cell Death Dis, 2021, 12(5):495

PubMed: 33993198 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:675486

PubMed: 34164397 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Sci Rep, 2021, 11(1):16243

PubMed: 34376787 ( click the link to review the publication )

Cancer Med, 2021, 10.1002/cam4.4018

PubMed: 34076346 ( click the link to review the publication )

Molecules, 2021, 26(9)2607

PubMed: 33946996 ( click the link to review the publication )

Oncol Lett, 2021, 21(4):295

PubMed: 33732371 ( click the link to review the publication )

Biology (Basel), 2021, 10(8)767

PubMed: 34439999 ( click the link to review the publication )

Can J Physiol Pharmacol, 2021, 10.1139/cjpp-2020-0588

PubMed: 33617370 ( click the link to review the publication )
J Orthop Surg Res, 2021, 16(1):160

PubMed: 33637095 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(2):33

PubMed: 33616621 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16313

PubMed: 33507617 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

Cell Rep, 2020, 21;31(3):107521

PubMed: 32320667 ( click the link to review the publication )

Int J Cancer, 2020, 7

PubMed: 32383186 ( click the link to review the publication )

Stem Cell Reports, 2020, S2213-6711(20)30192-2

PubMed: 32589876 ( click the link to review the publication )

J Clin Endocrinol Metab, 2020, dgaa656

PubMed: 32936899 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):488

PubMed: 33198821 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 20;2020:1868764

PubMed: 32377291 ( click the link to review the publication )

Proc Biol Sci, 2020, 287(1935):20192939

PubMed: 32933441 ( click the link to review the publication )

Chemosphere, 2020, 6;254:126709

PubMed: 32348926 ( click the link to review the publication )

Front Cell Neurosci, 2020, 14:575690

PubMed: 33343302 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6410

PubMed: 32899202 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Dev Biol, 2020, 457(1):128-139

PubMed: 31550483 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.2873

PubMed: 32030915 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2610-2620

PubMed: 33125122 ( click the link to review the publication )

Neural Plast, 2020, 2020:8815195

PubMed: 32802036 ( click the link to review the publication )

Front Pharmacol, 2020, 11:204

PubMed: 32194421 ( click the link to review the publication )

Dev Cell, 2019, 51(6):665-674.e6

PubMed: 31813796 ( click the link to review the publication )

J Cell Biol, 2019, 218(9):3134-3152

PubMed: 31371388 ( click the link to review the publication )

Elife, 2019, 8e50208

PubMed: 31482846 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )
Hum Mol Genet, 2019, 28(6):896-911

PubMed: 30445456 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(8)E1991

PubMed: 31018557 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5386-5395

PubMed: 30367510 ( click the link to review the publication )

J Cell Biochem, 2019, 120(11):18979-18994

PubMed: 31245876 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2019, 124(6):660-669

PubMed: 30548093 ( click the link to review the publication )

Hepatobiliary Pancreat Dis Int, 2019, 18(1):38-47

PubMed: 30243878 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):269-289

PubMed: 29263200 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Lab Chip, 2018, 18(20):3184-3195

PubMed: 30204194 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Mol Pain, 2018, 14:1744806918767560

PubMed: 29607715 ( click the link to review the publication )

Biol Reprod, 2018, 98(4):480-490

PubMed: 29329377 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Cell Transplant, 2018, 27(3):393-406

PubMed: 29749250 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):995-1003

PubMed: 30106753 ( click the link to review the publication )

Int J Clin Exp Pathol, 2018, 11(5):2920-2930

PubMed: 31938417 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

PLoS Genet, 2017, 13(8):e1006951

PubMed: 28797033 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )
Cell Physiol Biochem, 2017, 44(5):1856-1868

PubMed: 29237157 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):568-578

PubMed: 27709831 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 89:147-156

PubMed: 28624529 ( click the link to review the publication )

Mol Immunol, 2017, 92:68-75

PubMed: 29054053 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5605-5619

PubMed: 29200875 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42495-42509

PubMed: 28477008 ( click the link to review the publication )

Dev Cell, 2016, 39(2):239-253

PubMed: 27720610 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):682-94

PubMed: 27113760 ( click the link to review the publication )

J Med Chem, 2016, 59(24):11050-11068

PubMed: 27736063 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Development, 2015, 142(15):2610-22

PubMed: 26116667 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Int J Mol Med, 2015, 35(6):1641-50

PubMed: 25872645 ( click the link to review the publication )

Insect Sci, 2015, 22(5):587-96

PubMed: 25154865 ( click the link to review the publication )

Data Brief, 2015, 4:22-31

PubMed: 26217756 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):544-59

PubMed: 24553082 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )

Dev Cell, 2013, 25(2):169-81

PubMed: 23602386 ( click the link to review the publication )

Mol Cancer, 2013, 12:66

PubMed: 23786654 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 5;32(1):7

PubMed: 23379358 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Cyclopamine (11-deoxojervine)是一种特异性Hedgehog (Hh)信号通路拮抗剂，作用于Smoothened (Smo)，在TM3Hh12细胞中IC50为46 nM。

靶点

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

体外研究

Cyclopamine 抑制Hedgehog信号通路， IC50 为46 nM, 且在[3H]Hh-Ag结合实验中，作用于CHO-K1细胞，抑制人类Smo受体活性，IC50为 280 nM。^[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞，显著抑制 Hedgehog通路活性，这种作用存在剂量依赖性，且浓度为3 μM时，抑制肿瘤细胞生长，抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果，说明Cyclopamine 特定作用于Hedgehog 通路，且没有毒性。^[2]通过与Smo直接作用而抑制Hedgehog信号，Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖，抑制达 75-80%,且使凋亡率提高2.5到 3.5倍，但是不影响BxPC3-SMOlow 细胞系。^[3] Cyclopamine 处理E3LZ10.7细胞系，显著降低Snail mRNA，且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞，显著抑制浸润型细胞, 使转移细胞降低500多倍，但是对Hedgehog非依赖性细胞系Panc-1没有影响。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
OS-RC-2	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXXUV4NzUUN3ME21Mlg3PjZizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
DOHH-2	M1vyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVjJR\|UxRTlwM{W2PFkh\|ryP	NGf5XWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
no-10	M2\hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHPkUmlKSzVyPUmuPVA{QSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LS-513	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHLrbo9KSzVyPUGxMlM2PDdizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ALL-PO	NFTaZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHPCXIpKSzVyPUGxMlc4OzRizszN	M3ryN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
8-MG-BA	NFTWW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTF\|LkGxNlMh\|ryP	NIrVWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RPMI-8402	NUPrRWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXHxd2R3UUN3ME2xOU45PTN5IN88US=>	NV7sc5Q{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
EoL-1-cell	NWe5R3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlXwTWM2OD1zOD61PVQ5KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NALM-6	NGHsWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTF7LkCxOlch\|ryP	NGHQVpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
DEL	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFjKPWhKSzVyPUKwMlE1PzFizszN	NUDPc4E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SR	NWK0SVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MU\JR\|UxRTJ\|Lk[3NVUh\|ryP	MnrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
697	M3i0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWDKfGlrUUN3ME2yOk43OTV3IN88US=>	NXLqNVdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
COLO-829	NVO3[5dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUfJR\|UxRTJ4Lki0PFMh\|ryP	NEO5NJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
EVSA-T	M1WwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{HOUWlEPTB;MkeuOVU3OSEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ATN-1	NVTqcWJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXUcnJNUUN3ME2zNU4zOzJ7IN88US=>	NXvte5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
L-363	NUXme5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTNzLke0OlEh\|ryP	M4HLT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LAMA-84	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGe5c\|dKSzVyPUOyMlUzOTFizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NOS-1	M1XINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEPPcFFKSzVyPUO0MlI6PTZizszN	M1TafVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BB30-HNC	NV7uSGpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1vrUGlEPTB;M{SuN\|MxPiEQvF2=	Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BC-1	MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX6wNFk1UUN3ME2zO{46PzR4IN88US=>	NGLlOYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
IST-SL2	NWLZT45NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4[0fGlEPTB;M{iuNlI1KM7:TR?=	NWHIc2xZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
D-392MG	NHTrSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGnJfIxKSzVyPUSwMlIzOTVizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
no-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLlTWM2OD12MD61OVIyKM7:TR?=	NWq3ZZBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LC4-1	NV2w[INCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHnHXolKSzVyPUSwMlg4OTZizszN	NVnifHIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
A388	NEjSe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mne4TWM2OD12Mj61PFQ5KM7:TR?=	MlfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NIfpc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUjJR\|UxRTR{LkewO\|Qh\|ryP	NXfKfXlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CESS	NHrt[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEX0dWhKSzVyPUS0MlIzOzJizszN	MoHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
RS4-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWTzR3FRUUN3ME20PU4xQTN6IN88US=>	NGK0d4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MS-1	NGC0fYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjaXJJ4UUN3ME21NE46OzVzIN88US=>	NW\pdZl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CTV-1	M1X6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYX6[GZ[UUN3ME21NU4xPzRizszN	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
D-502MG	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnHzTWM2OD13MT62NlcyKM7:TR?=	MoXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ML-2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NILkR5pKSzVyPUWyMlkyQTVizszN	Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NInBSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUPpWpdyUUN3ME21N{4{QTJ\|IN88US=>	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LOXIMVI	M{nrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWjD[XVyUUN3ME21N{42QDh2IN88US=>	NWfS[m5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
DJM-1	NEexS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGDtW\|JKSzVyPUW2MlM{QTFizszN	NEDRRVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GI-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmPCTWM2OD13Nj62NVQ6KM7:TR?=	NHmwN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
IST-MES1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFrIWnVKSzVyPU[wMlU1QTNizszN	M2XlOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MV-4-11	MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\uc2lEPTB;NkCuOlU{QCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
OVCAR-4	NFjJeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml\KTWM2OD14Mz61OlU4KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KE-37	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV30fmF[UUN3ME22Ok4zPjZ6IN88US=>	NFXuPGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
D-542MG	NUTGUXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYjJR\|UxRTZ6LkSxN\|Uh\|ryP	NFL3ZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MHH-PREB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGfZbGxKSzVyPUeyMlg1PDFizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	M3fQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XuN2lEPTB;N{OuOFcxPSEQvF2=	MlXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
D-247MG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVHJR\|UxRTd\|LkW0OFIh\|ryP	NUDYRXcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
OCI-AML2	M{GyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEXiTnZKSzVyPUe2Mlk{PjlizszN	M4rCfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LP-1	NFPYcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MofYTWM2OD16Mj64O\|MyKM7:TR?=	Ml7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HCC1599	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV\DNlZsUUN3ME24OE4zQDN5IN88US=>	NIfiZY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KARPAS-45	NE\hR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVi1cYptUUN3ME24OE43QTl{IN88US=>	NYfSU3BnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BE-13	NXmxcWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX7JR\|UxRTl7LkC0O\|ch\|ryP	M1rFfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
GCIY	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3:xd2lEPTB;OUmuNFk2PCEQvF2=	M3vGPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
BV-173	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTFyMD6zNlUh\|ryP	MoXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnvQTWM2OD1zMECuO\|g6KM7:TR?=	MlrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
KS-1	NV31PJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknoTWM2OD1zMEGuOlM6KM7:TR?=	Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MOLT-16	NFrwW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3PSUmlEPTB;MUC0Mlk5PiEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1770	NV\ic2VCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4HvcmlEPTB;MUC4Mlc5PCEQvF2=	MlLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H82	NUHP[ohET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M373SWlEPTB;MUGwMlk4PiEQvF2=	NFnT[lU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCCIT	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnvQTWM2OD1zMUKuOVI6KM7:TR?=	NYT6PXdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KALS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVLK[WZ3UUN3ME2xNVUvQTRzIN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB2241-RCC	M2XsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFXtXXRKSzVyPUGxOk43PzlizszN	NILGcVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HH	M{XJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2DSV2lEPTB;MUG3MlM6PSEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HD-MY-Z	NX62OZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUPJR\|UxRTFzOD60PFgh\|ryP	NVHCN2Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
EB-3	NVP5OVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTF{Mz6wPVQh\|ryP	NY\xPJRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
BL-70	NWDmNIg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV;JR\|UxRTF{Mz6xNlch\|ryP	NX;lbG17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
K-562	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFW3RpJKSzVyPUGyOk4zPDVizszN	NH3XZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HT-144	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M37OZ2lEPTB;MUOzMlE3PCEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
PF-382	NVzUbFZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYK0T5VQUUN3ME2xN\|QvOzZzIN88US=>	NYj5d3p7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
RPMI-8226	NIHPenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFHwRplKSzVyPUGzOU4xPDVizszN	NH3ON5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H1355	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoDSTWM2OD1zM{WuOVg4KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LXF-289	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHnOfoVKSzVyPUGzPU44QDFizszN	M2TnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NCI-H69	NHO5XFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXTiWG9wUUN3ME2xOFIvQTN{IN88US=>	NEHuPXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
SK-MEL-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVzJR\|UxRTF2Nz6xN{DPxE1?	M{K2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KARPAS-299	M3n1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Moe1TWM2OD1zNEmuNVIh\|ryP	NEKze4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GB-1	NHnMc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUmyZ\|hFUUN3ME2xOFkvOzJ{IN88US=>	MnLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
CMK	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV3JR\|UxRTF2OT61NVUh\|ryP	M2fUcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MPP-89	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn3PTWM2OD1zNU[uNFM2KM7:TR?=	M2XMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KU812	M{Kzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlnSTWM2OD1zNkGuPVAzKM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
REH	NF\aVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYSze4toUUN3ME2xOlIvOTJ3IN88US=>	NXfJdnhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NEC8	NHLXUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NImyNHdKSzVyPUG2OU4xOjZizszN	NGm4XIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KP-N-YS	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\2fmxLUUN3ME2xOlgvOzl3IN88US=>	NVPRZpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	NV\YT5cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFXmTpZKSzVyPUG2PU46OTVizszN	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
Becker	NIHjToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGHOdJRKSzVyPUG3OE4yQCEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
LB647-SCLC	M{n4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTF5NT64OFUh\|ryP	NUnmNYN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LU-139	NGjHToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PGVmlEPTB;MUe4MlAyQSEQvF2=	NIGzfFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
QIMR-WIL	M37ndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3zHbmlEPTB;MUe5MlY1PiEQvF2=	MnSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1395	NHvsd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmHhTWM2OD1zN{muPVk3KM7:TR?=	MnzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NOMO-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MojxTWM2OD1zOEKuPFUh\|ryP	NGmxU4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
GI-ME-N	MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTF6Nz65Olkh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KMS-12-PE	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIDCdJVKSzVyPUG4PU4zPzNizszN	NXzJN5BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Daudi	M4\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEjZOlRKSzVyPUG5NU4yOjhizszN	M1i4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB996-RCC	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG\UdoxKSzVyPUG5NU43QTlizszN	NETwNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
NCI-H2107	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFX0UGlKSzVyPUG5N{44OzlizszN	MoO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	NX;OUVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIPqfnFKSzVyPUG5OE44OTlizszN	MlzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
MC-CAR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3nyOmlEPTB;MkCyMlI2OyEQvF2=	MmDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
SNB75	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3qybWlEPTB;MkKxMlk1KM7:TR?=	M13xZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ES4	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVjpO5hYUUN3ME2yNlMvPzh\|IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KARPAS-422	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmH2TWM2OD1{MkiuN\|UzKM7:TR?=	MoTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H1648	NIDxUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV:5NI9tUUN3ME2yNlkvPDh7IN88US=>	M4nLZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
ES6	NWKxc4NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkLkTWM2OD1{M{muOFMh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KNS-81-FD	NYi4dFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFXneHdKSzVyPUK0NU4yQTdizszN	NXzLWlZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
JAR	NIXXXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTJ3Nj6yNlUh\|ryP	NVnJToNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
NB1	NVjh[Fg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HNWGlEPTB;Mk[wMlUyPiEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
D-336MG	M1TwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoLuTWM2OD1{NkCuOlk5KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
BC-3	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXPNOph1UUN3ME2yOlUvOTd6IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
HCC2218	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUHJR\|UxRTJ4Nj60NVUh\|ryP	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
TE-9	M2LwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWPJV2Y5UUN3ME2yOlYvPjJ5IN88US=>	M1;JSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
LB1047-RCC	NH\XOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTJ4Nj63OVMh\|ryP	NV7wV3lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
CTB-1	NHT6d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjoNII5UUN3ME2yOlkvQTd\|IN88US=>	M4THPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
NB7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXiwW4ZDUUN3ME2yO\|Eh\|ryP	NFrxN4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ST486	NEfzeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUe3cYhjUUN3ME2yO\|cvPDF{IN88US=>	NHjQZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HCC1187	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkLGTWM2OD1{OEKuPFEyKM7:TR?=	MoPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-16	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrDTWM2OD1{OESuNlQ5KM7:TR?=	MnrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
COR-L279	M1HSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXzJR\|UxRTJ7MT61PFQh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
ES8	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkHlTWM2OD1{OUSuNVgzKM7:TR?=	Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U-698-M	NHzUXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGS4N3lKSzVyPUK5PE4zPDNizszN	M{DTOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
HEL	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGju[lBKSzVyPUOwPU4yPDlizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KINGS-1	NX7zPI85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MorMTWM2OD1\|MUCuOlc1KM7:TR?=	M3LVb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
KY821	M1jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnPUTWM2OD1\|M{[uOVk2KM7:TR?=	NILheGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
MZ1-PC	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH:4XFhKSzVyPUO0OU43OThizszN	NYTlTHM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
LS-411N	NVzveoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXLJR\|UxRTN3ND62OkDPxE1?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
SIG-M5	M2\vOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWm2PXJ1UUN3ME2zOVkvPzh{IN88US=>	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HT	NHHhSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTN4Nz63NVEh\|ryP	MmjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
HC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1LkemlEPTB;M{[3Mlc5PyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NCI-H1694	M1e4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEm1THBKSzVyPUO3Nk46OzRizszN	MoX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
BB65-RCC	M1;pV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUXWcGxUUUN3ME2zO\|YvOjR3IN88US=>	NFPFNG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HAL-01	NYDKfHJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTN5OT64N\|gh\|ryP	NGD0Wng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
ARH-77	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2HkcWlEPTB;M{m0MlAxQCEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
MZ7-mel	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVnMNoZlUUN3ME2zPVcvOjN\|IN88US=>	NFvabnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
SIMA	NEfrVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnXYTWM2OD12MEOuPVM{KM7:TR?=	M1fjclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
DG-75	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2jqWmlEPTB;NEG1MlY6QCEQvF2=	NHe5Wms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
HUTU-80	M{PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2TQ[WlEPTB;NEG5MlE5PSEQvF2=	NILUeWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KNS-42	M4n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnTrTWM2OD12MkWuPFE2KM7:TR?=	NYW5S3RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
SH-4	NX3xRndHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXSzV2ZCUUN3ME20NlcvPTZ3IN88US=>	NIno[VQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
L-540	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPLW\|NzUUN3ME20N\|EvODNzIN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
NB10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFXtfVBKSzVyPUS0NU4zOzRizszN	NXrDNpl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
ES1	M1vlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX7JR\|UxRTR3Mj63OVMh\|ryP	NYS4cVhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
KMOE-2	NYfKbod1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnzkTWM2OD12NU[uO\|EyKM7:TR?=	M1nlRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
MC116	NVfCNWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXvKNYlFUUN3ME20OVgvOTF4IN88US=>	M2m2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2PDF{OT:nQnNCVkeHUkyvZV4>
RCC10RGB	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXzl[npyUUN3ME20OlAvODB3IN88US=>	NFq5UJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
RL95-2	NEGw[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVi4VlVoUUN3ME20OlAvOjN5IN88US=>	NXjJOJFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjV2MUK5M{c,W0GQR1XSQE9iRg>?
Raji	M4PyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXPLXGxlUUN3ME20OlgvOTR\|IN88US=>	MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
CAS-1	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUHscnZuUUN3ME20O\|IvODd\|IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
Calu-6	M3G5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{fQcGlEPTB;NEe1MlI3PSEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOVQyOjlxJ{7TRW5ITVJ:L3G+
KG-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH7RTHNKSzVyPUS3PE41PCEQvF2=	MkH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
LB771-HNC	NWHVe5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPPTWM2OD12OEKuNlMzKM7:TR?=	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
ACN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2nLbmlEPTB;NEmzMlU6QSEQvF2=	NEfVV\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPTRzMkmvK\|5USU6JRWK8M4E,
KM12	M{fUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV;yVW01UUN3ME20PVYvPTh7IN88US=>	Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlU1OTJ7Lze+V2FPT0WUPD;hQi=>
U2OS	NVLaZpc5TnWwY4Tpc44h[XO\|YYm=			MmXiRolv\GmwZzDh[oZqdmm2eTD0c{B4cWymIIT5dIUhW22xIHX4dJJme3OnZDDpckBWOk:VIHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEumIE2gNE4xOTJ2IN88UU4>	NEHueGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
U2OS	MljCSpVv[3Srb36gZZN{[Xl?		MX:yJIhzew>?	MUXEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODF{NzFOwG0v	MnzhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
TM3	MWTGeY5kfGmxbjDhd5NigQ>?		M{nNcFQ5KGi{cx?=	MkW3TY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCWTUOgZ4VtdHNiYnXhdolv\yCyVFGtPJhIdGlvTIXjJJJmeG:{dHXyJINwdnO2coXjeEBie3Onc4Pl[EBieyC2cnHud4NzcXC2aX;uZYwhdW:mdXzheIlwdiCxZjDHcIkh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4Uh[XO\|YYmsJGlEPTBiPTCwMlA1PiEQvF2u	NGfY[XQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC5NVU2QSd-MUmwPVE2PTl:L3G+
HCC827	MUDGeY5kfGmxbjDhd5NigQ>?			NVe1[mZbTGm\|cHzhZ4Vu\W62IH;mJHs{UF1vY4njcI9x[W2rbnWg[pJwdSCVTV:gWlQxPE1ibYX0ZY51KGmwIHfl[ol1cW6rYjDy[ZNqe3SjboSgbJVu[W5iSFPDPFI4KGOnbHzzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtqKD1iMD6wOVEh\|ryPLh?=	M{X3d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{i3NVU3Lz5{OEe4O\|E2PjxxYU6=
HEK293	NGSwOZdHfW6ldHnvckBie3OjeR?=		M4nMVVIhcHK\|	NVLCR2lUTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3sZYJmdGynZDDjfYNtd3CjbXnu[UBnem:vIHj1cYFvKFOvbzDy[YNmeHSxcjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5MEBKSzVyIE2gNE4xPjRizszNMi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
Shh Light2	NFOwOHhHfW6ldHnvckBie3OjeR?=		NEG2dZU{OCCqcoO=	MmrVTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCVaHigUIlocHR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhe2:waXOgbIVl\2Wqb3etbY5lfWOnZDDHUGkyNW2nZHnheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBu\WG\|dYLl[EBi\nSncjCzNEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlA4PDFizszNMi=>	NFru[Ho9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W2O\|M4OSd-Mke1Olc{PzF:L3G+
U2OS	NVjCNnBrTnWwY4Tpc44h[XO\|YYm=			MmfqRolv\GmwZzDh[oZqdmm2eTD0c{BUdW9iRES3N2ghdXW2YX70JIV5eHKnc4Pl[EBqdiCXMl;TJINmdGy\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvkJF0hOC5zMU[g{txONg>?	NWf2OWg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlM2OjJpPkKzNFY{PTJ{PD;hQi=>
DaOY	M3ywfWZ2dmO2aX;uJIF{e2G7		NGnjU4s1QCCqcoO=	M{LrWmlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJIh2dWGwIFThU3kh[2WubIOgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhT2yrMTDtVm5CKGW6cILld5Nqd25iYX\0[ZIhPDhiaILzJIJ6KFKWLWDDVkBidmGueYPpd{whUUN3MDC9JFAvOTZizszNMi=>	NIO5U3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
U2OS	M3y3VGZ2dmO2aX;uJIF{e2G7		NUD4N5FyOiCqcoO=	NVnENYVKTGm\|cHzhZ4Vu\W62IH;mJHs{UF2leXPsc5BidWmwZTDmdo9uKFOvbzDEOFc{UCCvdYThcpQh\XiycnXzd4VlKGmwIGWyU3Mh[2WubIOgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2liPTCwMlI{OiEQvF2u	NF;jb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2N\|UzOid-MkOwOlM2OjJ:L3G+
CHO	M1q1eWZ2dmO2aX;uJIF{e2G7			NVr3emRMSW62YXfvcol{fCCjY4Tpeol1gSCjdDDoeY1idiCVbX:gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCkeTDbN2heUGhvQXegZolv\GmwZzDhd5NigSxiSVO1NEA:KDBwMkig{txONg>?	NY\MT3gxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwPVE2PTlpPkG5NFkyPTV7PD;hQi=>
Shh Light2	M3T5bGZ2dmO2aX;uJIF{e2G7		NGPTTpQ1OCCqcoO=	NFTENIRKdmirYnn0bY9vKG:oIGPITEBx[XSqd3H5JIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZYZ1\XJiNECgbJJ{KGK7IFfsbU1l\XCnbnTlcpQhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD6zJO69VS5?	NYLwVVBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1PVI4QDhpPkKxOVkzPzh6PD;hQi=>
Shh-light2	Mn24SpVv[3Srb36gZZN{[Xl?			MULJcohq[mm2aX;uJI9nKFOvbz3t[YRq[XSnZDDIbEB{cWewYXzpcochcW5iaIXtZY4hW2iqLXzp[4h1OiClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGlEPTBiPTCwMlMh\|ryPLh?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEW1NUc,OjJ{Nki1OVE9N2F-
M210B4	M2DlSWZ2dmO2aX;uJIF{e2G7		M3WzcFI1KGi{cx?=	M1rEb2lvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCSdHPoJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC52MzFOwG0v	M1j2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|E3Lz5{NEmwNFcyPjxxYU6=
Shh-Light 2	NYDLSlhHTnWwY4Tpc44h[XO\|YYm=		M1HWTVIh\GG7cx?=	NXPwe\|dLSW62YXfvcol{fCCjY4Tpeol1gSCjdDDTcY8hcW5ibX;1d4UhW2iqLVzp[4h1KDJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBUcGhvaX7keYNm\CCJbHmxMZJmeG:{dHXyJIFkfGm4aYT5JIFnfGW{IEKg[IF6eyCkeTDkeYFtNWy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBu\XSqb3SsJGlEPTBiPTCwMlQ5PCEQvF2u	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4M{WyNkc,OjNyNkO1NlI9N2F-
Shh Light2	MXvGeY5kfGmxbjDhd5NigQ>?			NUTVd5BNUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqIFzp[4h1OiClZXzsd{BjgSCJTFmtdoV{eG:wc3n2[UBncXKnZnz5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNTFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyOUC4NEc,OTl\|MEmwPFA9N2F-
C3H10T1/2	M3nSU2Z2dmO2aX;uJIF{e2G7			NU\ROZFoUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJHNJUCCjY4TpeoF1\WRicHH0bJdigSCrbjDtc5V{\SCFM1ixNHQyNzJiY3XscJMh[XO\|ZYPz[YQh[XNiU1HHMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44h[nliYXzrZYxqdmVicHjvd5Bp[XSjc3WgZZN{[XluIFnDOVAhRSByLk[g{txONg>?	NEPWV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW5Nlc5QCd-MkG1PVI4QDh:L3G+
C3H10T1/2	NYfUcHR7TnWwY4Tpc44h[XO\|YYm=		M2q3dFYhcHK\|	MYjJcohq[mm2aX;uJI9nKFODRz3pcoR2[2WmIHTp[oZmemWwdHnheIlwdiCxZjDtc5V{\SCvZYPlcoNpgW2jbDDwcJVzcXCxdHXueEBEO0hzMGSxM\|Ih[2WubIOgeI8h[WytYXzpcoUheGixc4DoZZRie2VicH;zbZRqfmVib3Xz[Y9jdGG\|dIOgZYZ1\XJiNjDodpMtKEmFNUCgQUAxNjZ{IN88UU4>	M37KSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVUyLz5{MkK2PFU2OTxxYU6=
ASZ001	MUnGeY5kfGmxbjDhd5NigQ>?		MXy0PEBpenN?	M1H2OGlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIFHTXlAxOSClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC54NjFOwG0v	NYXFOId2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OTZpPkK0PVAxPzF4PD;hQi=>
M210B4	MmCySpVv[3Srb36gZZN{[Xl?		MlPINlQhcHK\|	M4f2PWlvcGmkaYTpc44hd2ZiSHXk[4Vpd2dic3nncoFtcW6pIHnuJI1wfXOnIF2yNVBDPCClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCJbHmxJI1TVkFiZYjwdoV{e2mxbjDh[pRmeiB{NDDodpMh[nliUmStVGNTKGGwYXz5d4l{NCCLQ{WwJF0hOC56IN88UU4>	NIO1SVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyPid-MkS5NFA4OTZ:L3G+
medulloblastoma cells	M1rINmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			M3;jWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibXXkeYxtd2KuYYP0c41iKGOnbHzzJIhiemKxcnnu[{Bp\XSncn;6fYdwfXNicITjbFEh\2WwZTDifUBOXFRiYYPzZZktKEWFNUCgQUAyKM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
CHO	NGjmVWZHfW6ldHnvckBie3OjeR?=			NVG0RY13SW62YXfvcol{fCCjY4Tpeol1gSCjdDDtc5V{\SCVbX:gdoVk\XC2b4Kg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCkeTDbN2heUGhvQXegZolv\GmwZzDhd5NigSxiSVO1NEA:KDFwMjFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB7MUW1PUc,OTlyOUG1OVk9N2F-
Shh-Light2	MmPpSpVv[3Srb36gZZN{[Xl?		NYDmclhrPDhiaILz	NYTZTFVXUW6qaXLpeIlwdiCxZjDTTGghcW5ibX;1d4UhW2iqLVzp[4h1OiClZXzsd{Bi\nSncjC0PEBpenNiYomgS4xqOSC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKFODRzygTWM2OCB;IEGuN\|EzKM7:TT6=	M2Ph[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFkxLz5zOUW0NVQ6ODxxYU6=
MEF	M2TJTGZ2dmO2aX;uJIF{e2G7			NEP2RZBKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBRfGOqLXTl[olkcWWwdDDNSWYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTbIgucW6mdXPl[EBIdGlzIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSxiSVO1NEA:KDFwNTFOwG0v	MnzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{S1OFEoRjJ\|MEe0OVQyRC:jPh?=
MEF	M{TSU2Z2dmO2aX;uJIF{e2G7		NX7h[XNXOzBiaILz	NIrUe2dKdmirYnn0bY9vKG:oIGPtc{BqdiCvb4Xz[UBRfGOqLXTl[olkcWWwdDDNSWYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTbIgucW6mdXPl[EBIdGlvcnXzdI9ve2m4ZTDi[ZRi\2GuYXP0c5Nq\GG\|ZTDhZ5Rqfmm2eTDh[pRmeiB\|MDDodpMh[nliQnX0ZWdNdyCjc4PhfUwhUUN3MDC9JFEvQSEQvF2u	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
neural precursor cells	MnS0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NHPFV5NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIH7leZJidCCycnXjeZJ{d3JiY3XscJMh[nliY3;sc456KG[xcn3heIlwdiCjc4PhfUwhTUN3MDC9JFE{NjR2IN88UU4>	NVHycYtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
U87	NEWzVotEgXSxdH;4bYNqfHliYYPzZZk>			NH\M[Y5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQDdiY3XscJMh[XO\|ZYPz[YQh[XNidnnhZoltcXS7IHnuJJBz\XOnbnPlJI9nKGKndHGg[4x2[3W{b37p[IF{\SxiSVO1NEA:KDF3LkWg{txONg>?	M2HMTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUG2PVA1Lz5{MEGxOlkxPDxxYU6=
U87MG	NFLJb4dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV7KU4pqPzJiaILz	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB{Mj61JO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ{Nk[1O{c,OjJ{Mk[2OVc9N2F-
A549	Mmi0RY51cWOjbnPldkBie3OjeR?=			M3Tj[2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDR7IN88UU4>	M1P1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkKxPFczLz5zOEKyNVg4OjxxYU6=
DU145	M{HM[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3XzRVUhfU1?	NYLyN2dvQTZiaILz	M3fHfGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGG2IEWgeW0h[W[2ZYKgPVYhcHK\|	MmLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEmxNlUoRjF6MkS5NVI2RC:jPh?=
DU145	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmPhNVAhfU1?	M1fCc\|k3KGi{cx?=	MXnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BifCBzMDD1UUBi\nSncjC5OkBpenN?	NEnyU5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0PVEzPSd-MUiyOFkyOjV:L3G+
HEK293	M{XzZWZ2dmO2aX;uJIF{e2G7			M4Ple2lvcGmkaYTpc44hd2ZiYnX0ZUBo[WyjY4Tvd4ll[XOnIHnuJGhGUzJ7MzDj[Yxtew>?	Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OUS3OlYoRjF5NEm0O\|Y3RC:jPh?=
22Rv	NEK5SZlHfW6ldHnvckBie3OjeR?=			NFi5NmRT\WS3Y4Tpc44hd2ZiZYjwdoV{e2mxbjDv[kBRXEOKIH3SUmEhcW5iaIXtZY4hOjKUdjDj[Yxtew>?	NYrIcopIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0PVQ4PjZpPkG3OFk1PzZ4PD;hQi=>
PANC1	MVzGeY5kfGmxbjDhd5NigQ>?	NHTISXUxNjJidV2=	MlPaNlQhcHK\|	NEjjcVZKdmirYnn0bY9vKG:oIFjoM2dNUTFvbXXkbYF1\WRiUGTDTEBuWk6DIHX4dJJme3Orb36gbY4hcHWvYX6gVGFPSzFiY3XscJMh[XRiMD6yJJVOKGGodHXyJFI1KGi{czDifUBTXC2SQ2K=	NWLoVZhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVAyPzBpPkKwOFUxOTdyPD;hQi=>
PANC1	NV2zXItjTnWwY4Tpc44h[XO\|YYm=	Mn3INE41KHWP	NWj4UodmOjRiaILz	NWHpWnJlUW6qaXLpeIlwdiCxZjDIbE9IVElzLX3l[IlifGWmIGDUR2ghdVKQQTDlfJBz\XO\|aX;uJIlvKGi3bXHuJHBCVkNzIHPlcIx{KGG2IECuOEB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPS	M{\jZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWwNVcxLz5{MES1NFE4ODxxYU6=
Shh Light2	MmDvSpVv[3Srb36gZZN{[Xl?	NYDtS5gyPi5{NTD1US=>	MlTDN\|AhcHK\|	NWTPbFV1UW6qaXLpeIlwdiCxZjDOMZBidG2rdH;5cIF1\WRiU3joJIlvKG2xdYPlJHNpcCCOaXfoeFIh[2WubIOgZZQhPi5{NTD1UUBi\nSncjCzNEBpenNiYomg[olz\W[ueTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	NXLWenNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxOVE4OzFpPkG5NVUyPzNzPD;hQi=>
U87MG	M3Lm[WZ2dmO2aX;uJIF{e2G7	MoD0NVAhfU1?	NGLOboY1KGi{cx?=	MoXPTY5pcWKrdHnvckBw\iCKZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDoeY1idiCXOEfNS{Bk\WyuczDhd5Nme3OnZDDhd{Bld3ewIILl[5Vt[XSrb36gc4YhT2yrMTDheEAyOCC3TTDh[pRmeiB2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZM>	NXq4XYVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNlY3PTdpPkKyNlI3PjV5PD;hQi=>
HEK293	MV\GeY5kfGmxbjDhd5NigQ>?	M3PtRVUhfU1?	Ml3lNVAhcHK\|	MoHxSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2leXPsc5BidWmwZTDmdo9uKGi3bXHuJHNudyCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG2IEWgeW0hdWWjc4Xy[YQh[W[2ZYKgNVAhcHK\|IHL5JGRCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIH3pZ5Jwe2OxcHnjJIF{e2G7	NHH6[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ezOlA3Oyd-Mke3N\|YxPjN:L3G+
HEK293	MmrrSpVv[3Srb36gZZN{[Xl?	NHjNcXo2KHWP	M3HF[\|ExKGi{cx?=	M4fFd2Rqe3CuYXPlcYVvfCCxZjDCU2RKWFlvY4njcI9x[W2rbnWg[pJwdSCqdX3hckBUdW9iZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjdDC1JJVOKG2nYYP1doVlKGGodHXyJFExKGi{czDifUBHSUOVIHHuZYx6e2m\|	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd\|NkC2N{c,Ojd5M{[wOlM9N2F-
C3H10T1/2	MlLRSpVv[3Srb36gZZN{[Xl?	M2\BPVU2NjVidH:gOFUxOCCwTR?=		M121dmNwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gV41wKGmwIH3veZNmKEN\|SEGwWFEwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNCTy2rbnT1Z4VlKEeuaUGgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHH0JFU2NjVidH:gOFUxOCCwTTDifUByWEOUIHHuZYx6e2m\|	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5NEW0NUc,OjNyN{S1OFE9N2F-
U2OS	MWTGeY5kfGmxbjDhd5NigQ>?	M1rrU\|UhfU1?	MW[2JIhzew>?	MmjlRY51[WexbnnzeEBi[3Srdnn0fUBifCClaHnt[ZJq[yCVbX:gOlM{KG23dHHueEBmgHC{ZYPz[YQhcW5iVULPV{Bk\WyuczDjc4V5eHKnc4Ppcoch[mW2YTDhdpJme3SrbkKtS2ZRKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhcW62cnHj[YxtfWyjcjDi[ZRiKGG{cnXzeIlvOi2JRmCgZYdoemWpYYTlJIZwem2jdHnvckBifCB3IIXNJIFnfGW{IE[gbJJ{KGK7IHPvcoZw[2GuIH3pZ5Jwe2OxcIm=	MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9.	26859575 26137001 23599805
Immunofluorescence	PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times. Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.	28747625 24553082

体内研究

Cyclopamine 每天按50 mg/kg剂量处理小鼠，持续22天，消除HUCCT1移植瘤，且没有明显副作用。^[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天，前者诱导明显的肿瘤细胞凋亡，后者降低肿瘤质量，降低达50-60%，但是作用于BxPC3-SMOlow肿瘤没有效果。^[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤，显著抑制肿瘤转移，且和 Gemcitabine联用处理，完全废除转移。^[4]

激酶实验：^[1]	- 合并激酶实验: Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数，测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验，然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上，与Cyclopamine在37^oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上，然后在37^oC下温育。48小时后，在实验板中加入Bright-Glo或MTS，然后在492 nm处测定发光度或吸光度。通过分析反应曲线，使用R统计软件包测定IC50值。
细胞实验：^[2]	- 合并 Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116 Concentrations: 溶于DMSO, 终浓度为3 μM Incubation Time: 4天 Method: 在96孔板上，用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定，进行2和4天，然后在490 nm处通过测定光密度而测定存活细胞。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠 Dosages: 50 mg/kg/day Administration: 皮下注射处理 (Only for Reference)

参考文献

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- 合并

溶解度 (25°C)

体外	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Cyclopamine SDF

分子量	411.62
化学式	C₂₇H₄₁NO₂
CAS号	4449-51-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	11-deoxojervine

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to reconstitute the compound for in vivo use in mice?
回答：
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Cyclopamine

客户使用Selleck生产的Cyclopamine发表文献110篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Cyclopamine SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品